The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that intensifies regulatory scrutiny on the pharmaceutical sector, the European Commission opened an investigation into French drugmaker Sanofi's flu vaccine marketing campaign, suspected of violating EU competition rules. The Commission stated the probe targets the marketing practices of the Paris-based company, which could result in fines or behavioral remedies.
The probe comes amid heightened regulatory focus on major vaccine producers in Europe, with Sanofi being a key player in the global flu vaccine market. If the violation is confirmed, the Commission can impose penalties of up to 10% of the company's annual revenue, potentially hitting its financial performance.
Sign in to access this content
Sign InSanofi's Paris-listed shares (SAN.PA) closed at €73.76 on June 25, while its New York-listed shares (SNY) ended at $41.80. Investors are closely watching the investigation's developments, with no immediate catalysts in sight, likely keeping pressure on the stock in the near term.